Related Experiment Video
Updated: May 29, 2025

08:04
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.6K
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53
Karlo Perica1,2, Nayan Jain2, Michael Scordo1,3,4
1Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.
The New England Journal of Medicine
|February 5, 2025
Abstract:
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case of a T-cell lymphoma harboring a lentiviral integration in a known tumor suppressor, TP53, which developed in a patient with multiple myeloma after B-cell maturation antigen (BCMA) CAR T-cell therapy.

